<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03369717</url>
  </required_header>
  <id_info>
    <org_study_id>2017-8460</org_study_id>
    <nct_id>NCT03369717</nct_id>
  </id_info>
  <brief_title>Use of Perioperative Antibiotics in Endoscopic Sinus Surgery</brief_title>
  <official_title>Use of Perioperative Antibiotics in Endoscopic Sinus Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine whether the use of postoperative antibiotics&#xD;
      following ESS decreases postoperative infection rates. This is a multi-institutional&#xD;
      prospective study involving Albert Einstein College of Medicine/Montefiore Medical Center,&#xD;
      Columbia University Medical Center, Weill Cornell Medical College, Mount Sinai Health System,&#xD;
      and New York University Langone Medical Center. The study design will be a&#xD;
      multi-institutional prospective randomized controlled trial with parallel random groups&#xD;
      assigned to receive postoperative antibiotics or no postoperative antibiotics. The&#xD;
      investigators hypothesize that patients who receive postoperative antibiotics will have lower&#xD;
      postoperative infection rates and improved postoperative sinonasal symptoms and nasal&#xD;
      endoscopy scores.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Expired IRB approval since 05/07/2020&#xD;
  </why_stopped>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in postoperative infection</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in postoperative endoscopy scores</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in postoperative SNOT-22 scores</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Chronic Sinus Infection</condition>
  <arm_group>
    <arm_group_label>Antibiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To receive postoperative antibiotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No antibiotics</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Will not receive any postoperative antibiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxi Clavulanate</intervention_name>
    <description>Postoperative antibiotics</description>
    <arm_group_label>Antibiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with CRS with or without nasal polyposis or allergic fungal rhinosinusitis&#xD;
             who present to the otolaryngology clinic who have been deemed suitable for bilateral&#xD;
             ESS, and are over the age of 18 will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with sinonasal tumors, allergies or adverse reactions to all of the&#xD;
             antibiotics that will be used in this study (amoxicillin-clavulanate, doxycycline,&#xD;
             clarithromycin), immunodeficiency, cystic fibrosis, pregnancy, or diabetes with nasal&#xD;
             polyposis (inability to receive systemic steroids) will be excluded, as will patients&#xD;
             who lack capacity to provide informed consent. Patients undergoing active treatment&#xD;
             for malignancy will be excluded. Patients undergoing unilateral ESS or with&#xD;
             nonabsorbable packing placed at the time of surgery will be excluded. Patients who&#xD;
             have been on antibiotics within 2 weeks of the surgery date will be excluded. Patients&#xD;
             with acute on chronic sinusitis or the presence of purulence at time of surgery will&#xD;
             be excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadeem Akbar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 6, 2017</study_first_submitted>
  <study_first_submitted_qc>December 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2017</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endoscopic sinus surgery</keyword>
  <keyword>antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

